CLL with trisomy 12 showed a characteristic response profile with multiple drug associations, including increased sensitivity to PI3K, mTOR, and MEK inhibitors (Figure 10B). This evidence concerns the gene PIK3CA and B-cell chronic lymphocytic leukemia.